Actinium Pharmaceuticals starts pursuit of EU Orphan Designation for Iomab-B
The Company anticipates the following events to occur over the coming months and will provide updates on its EU orphan designation progress as key milestones occur. In the
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Sarilumab is being developed by Sanofi and Regeneron Pharmaceuticals, while adalimumab is marketed by AbbVie as Humira. Sarilumab is a human monoclonal antibody directed against the interleukin-6 (IL-6)